In vivo biodistribution and ototoxicity assessment of cationic liposomal-ceftriaxone via noninvasive trans-tympanic delivery in chinchilla models : Implications for otitis media therapy
Copyright © 2024 Elsevier B.V. All rights reserved..
OBJECTIVES: We report the in vivo biodistribution and ototoxicity of cationic liposomal-ceftriaxone (CFX) delivered via ear drop formulation in adult chinchilla.
METHODS: CFX was encapsulated in liposomes with size of ∼100 nm and surface charge of +20 mV. 100 μl liposomes or free drug was applied twice daily in both external ear canals of adult chinchillas for either 3 or 10 days. Study groups included free ceftriaxone (CFX, Day 3: n = 4, Day 10: n = 8), liposomal ceftriaxone (CFX-Lipo, Day 3: n = 4, Day 10: n = 8), and a systemic control group (Day 3: n = 4, Day 10: n = 4). Ceftriaxone delivery to the middle ear and systemic circulation was quantified by HPLC assays. Liposome transport was visualized via confocal microscopy. Auditory brainstem response (ABR) tests and cochlear histology were used to assess ototoxicity.
RESULTS: Liposomal ceftriaxone (CFX-Lipo) displayed a ∼658-fold increase in drug delivery efficiency in the middle ear relative to the free CFX (8.548 ± 0.4638% vs. 0.013 ± 0.0009%, %Injected dose, Mean ± SEM). CFX measured in blood serum (48.2 ± 7.78 ng/ml) following CFX-Lipo treatment in ear was 41-fold lower compared to systemic free-CFX treatment (1990.7 ± 617.34 ng/ml). ABR tests and histological analysis indicated no ototoxicity due to the treatment.
CONCLUSION: Cationic liposomal encapsulation results in potent drug delivery across the tympanic membrane to the middle ear with minimal systemic exposure and no ototoxicity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:178 |
|---|---|
| Enthalten in: |
International journal of pediatric otorhinolaryngology - 178(2024) vom: 15. März, Seite 111894 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shafiee, Shayan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
75J73V1629 |
|---|
| Anmerkungen: |
Date Completed 15.03.2024 Date Revised 16.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijporl.2024.111894 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368404870 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368404870 | ||
| 003 | DE-627 | ||
| 005 | 20240316232747.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240214s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijporl.2024.111894 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1332.xml |
| 035 | |a (DE-627)NLM368404870 | ||
| 035 | |a (NLM)38350381 | ||
| 035 | |a (PII)S0165-5876(24)00048-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shafiee, Shayan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In vivo biodistribution and ototoxicity assessment of cationic liposomal-ceftriaxone via noninvasive trans-tympanic delivery in chinchilla models |b Implications for otitis media therapy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.03.2024 | ||
| 500 | |a Date Revised 16.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier B.V. All rights reserved. | ||
| 520 | |a OBJECTIVES: We report the in vivo biodistribution and ototoxicity of cationic liposomal-ceftriaxone (CFX) delivered via ear drop formulation in adult chinchilla | ||
| 520 | |a METHODS: CFX was encapsulated in liposomes with size of ∼100 nm and surface charge of +20 mV. 100 μl liposomes or free drug was applied twice daily in both external ear canals of adult chinchillas for either 3 or 10 days. Study groups included free ceftriaxone (CFX, Day 3: n = 4, Day 10: n = 8), liposomal ceftriaxone (CFX-Lipo, Day 3: n = 4, Day 10: n = 8), and a systemic control group (Day 3: n = 4, Day 10: n = 4). Ceftriaxone delivery to the middle ear and systemic circulation was quantified by HPLC assays. Liposome transport was visualized via confocal microscopy. Auditory brainstem response (ABR) tests and cochlear histology were used to assess ototoxicity | ||
| 520 | |a RESULTS: Liposomal ceftriaxone (CFX-Lipo) displayed a ∼658-fold increase in drug delivery efficiency in the middle ear relative to the free CFX (8.548 ± 0.4638% vs. 0.013 ± 0.0009%, %Injected dose, Mean ± SEM). CFX measured in blood serum (48.2 ± 7.78 ng/ml) following CFX-Lipo treatment in ear was 41-fold lower compared to systemic free-CFX treatment (1990.7 ± 617.34 ng/ml). ABR tests and histological analysis indicated no ototoxicity due to the treatment | ||
| 520 | |a CONCLUSION: Cationic liposomal encapsulation results in potent drug delivery across the tympanic membrane to the middle ear with minimal systemic exposure and no ototoxicity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Biodistribution study | |
| 650 | 4 | |a Liposomal-ceftriaxone | |
| 650 | 4 | |a Nanoparticle drug delivery | |
| 650 | 4 | |a Otitis media treatment | |
| 650 | 4 | |a Ototoxicity evaluation | |
| 650 | 4 | |a Trans-tympanic delivery | |
| 650 | 7 | |a Ceftriaxone |2 NLM | |
| 650 | 7 | |a 75J73V1629 |2 NLM | |
| 650 | 7 | |a Liposomes |2 NLM | |
| 700 | 1 | |a Hong, Wenzhou |e verfasserin |4 aut | |
| 700 | 1 | |a Lucas, Julliette |e verfasserin |4 aut | |
| 700 | 1 | |a Khampang, Pawjai |e verfasserin |4 aut | |
| 700 | 1 | |a Runge, Christina L |e verfasserin |4 aut | |
| 700 | 1 | |a Wells, Clive |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Ke |e verfasserin |4 aut | |
| 700 | 1 | |a Kerschner, Joseph E |e verfasserin |4 aut | |
| 700 | 1 | |a Joshi, Amit |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of pediatric otorhinolaryngology |d 1993 |g 178(2024) vom: 15. März, Seite 111894 |w (DE-627)NLM001226304 |x 1872-8464 |7 nnns |
| 773 | 1 | 8 | |g volume:178 |g year:2024 |g day:15 |g month:03 |g pages:111894 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijporl.2024.111894 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 178 |j 2024 |b 15 |c 03 |h 111894 | ||